Market research
069620.KO Daewoong pharmaceutical Co.,Ltd
KO KRW Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 1T
- P/E ratio
- Not available
- Analyst target
- 202000
- Dividend yield
- 0.5%
- Beta
- 0.03
Profile
Company facts
- Exchange
- KO
- Currency
- KRW
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- KR7069620003
- Market cap
- 1T
- P/E ratio
- Not available
- Analyst target
- 202000
- Dividend yield
- 0.5%
- Beta
- 0.03
About
About Daewoong pharmaceutical Co.,Ltd
Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 069620.KO discussion.
5 years, 5 months ago
Daewoong pharmaceutical Co.,Ltd is currently in a long term uptrend where the price is trading 17.1% above its 200 day moving average.
From a valuation standpoint, the stock is 84.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.3.
Daewoong pharmaceutical Co.,Ltd's total revenue sank by 7.1% to $267B since the same quarter in the previous year.
Its net income has increased by 458.7% to $18B since the same quarter in the previous year.
Finally, its free cash flow grew by 130.8% to $13B since the same quarter in the previous year.
Based on the above factors, Daewoong pharmaceutical Co.,Ltd gets an overall score of 4/5.